About this Guide

This guide provides supplementary information for the Cemiplimab (Libtayo) Dosing Schedule Calculator. It explains the calculator’s functions, outputs, and the clinical context for the Cemiplimab dosing regimen. This information is intended for qualified healthcare professionals as an educational resource and is not a substitute for clinical judgment or the full Prescribing Information.

Outputs

The calculator generates a clear, printable dosing schedule based on the inputs provided. The primary output is a table that includes:

• Cycle Number: The sequential number for each treatment cycle.
• Planned Date: The calculated date for each intravenous infusion.
• Day of Week: The corresponding day of the week for each planned date, aiding in clinic scheduling.
• Dose: The standard flat dose of 350 mg for the Q3W regimen.
• Notes: A blank column for manual notes, such as patient-specific instructions or dose modifications.

How to Use

To generate a dosing schedule with the tool above, follow these steps:

1. Select Indication: Choose the appropriate indication for Cemiplimab treatment from the dropdown list.
2. Confirm Regimen: The tool is pre-set to the 350 mg IV every 3 weeks (Q3W) regimen.
3. Set Start Date: Enter the planned start date for the first cycle of treatment.
4. Choose Cycle Count: Select the total number of treatment cycles you wish to display in the schedule.
5. Enter Patient Weight (Optional): Patient weight is not required for dose calculation but can be entered for documentation.
6. Calculate: Click the “Calculate Schedule” button to generate the complete dosing table.

Dosing Overview

Cemiplimab (Libtayo) is approved for several oncology indications, including advanced Cutaneous Squamous Cell Carcinoma (CSCC), Basal Cell Carcinoma (BCC), Non-Small Cell Lung Cancer (NSCLC), and Cervical Cancer. The standard flat-dose regimen, which this calculator is based on, is:

• Dose: 350 mg
• Frequency: Every 3 weeks (Q3W)
• Administration: Administered as an intravenous (IV) infusion over 30 minutes.

Treatment is typically continued until disease progression or unacceptable toxicity. Always consult the full Prescribing Information for detailed administration instructions and specific guidelines by indication.

Switching Regimens

This calculator is exclusively designed for the 350 mg Q3W regimen. The Prescribing Information also includes a 700 mg Q6W regimen. Switching between regimens should only be done under the direction of a qualified healthcare provider and in accordance with institutional guidelines. This tool cannot be used to calculate schedules for the Q6W regimen.

Missed Dose

If a planned dose of Cemiplimab is missed, it should be administered as soon as possible. The schedule for subsequent doses should be adjusted to maintain the 3-week interval between doses. Patients should be instructed to contact their healthcare provider immediately for guidance if they miss a scheduled appointment or infusion.

Safety Alerts

Frequently Asked Questions (FAQ)

What dosing regimen does this Cemiplimab calculator use?
This calculator is based exclusively on the Cemiplimab 350 mg administered intravenously every 3 weeks (Q3W) regimen.

Can I use this tool to calculate a schedule for the 700 mg every 6 weeks (Q6W) regimen?
No, this tool is specifically designed for the Q3W schedule and cannot be used for the Q6W regimen.

How are the treatment dates calculated?
The first date is the “Treatment Start Date” you provide. Each subsequent date is calculated by adding 21 days (3 weeks) to the date of the previous cycle.

Is patient weight required to use the calculator?
No. Patient weight is an optional field for record-keeping purposes. The 350 mg Q3W regimen is a flat dose and is not based on patient weight.

What should I do if a calculated date falls on a weekend or a public holiday?
The generated schedule is a mathematical projection. Clinical staff should adjust the infusion date to the nearest business day as per institutional policy and clinical judgment.

Does this calculator account for dose delays due to toxicity or illness?
No. The schedule is an ideal projection. Any real-world dose delays require a new baseline start date to be entered to recalculate the subsequent schedule accurately.

What indications is this tool intended for?
The tool allows you to select from the major approved indications for Cemiplimab, including CSCC, BCC, NSCLC, and Cervical Cancer, to document it on the output schedule.

Is the generated schedule a final treatment plan?
No. The schedule is a planning aid. All treatment plans must be confirmed by a healthcare professional and are subject to change based on the patient’s clinical status and tolerance to treatment.

References

The information and calculations are based on standard clinical practices and product labeling. Always consult the most current, full Prescribing Information from an official source before making any clinical decisions.

1. LIBTAYO® (cemiplimab-rwlc) Prescribing Information. U.S. Food and Drug Administration.
2. Libtayo (cemiplimab) Summary of Product Characteristics. European Medicines Agency.
3. Libtayo HCP Official Website. Regeneron Pharmaceuticals, Inc. and Sanofi.
4. Cemiplimab Professional Drug Information. Drugs.com.